Single-cell heterogeneity in Sézary syndrome-Reference-Cited by-同舟云学术

Single-cell heterogeneity in Sézary syndrome

Published:2018-08-23 Issue:16 Volume:2 Page:2115-2126
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Buus Terkild Brink¹^ORCID,Willerslev-Olsen Andreas¹^ORCID,Fredholm Simon¹^ORCID,Blümel Edda¹^ORCID,Nastasi Claudia¹^ORCID,Gluud Maria¹,Hu Tengpeng¹,Lindahl Lise M.²,Iversen Lars²,Fogh Hanne³,Gniadecki Robert³,Litvinov Ivan V.⁴,Persson Jenny L.⁵⁶,Bonefeld Charlotte Menné¹^ORCID,Geisler Carsten¹^ORCID,Christensen Jan Pravsgaard¹^ORCID,Krejsgaard Thorbjørn¹^ORCID,Litman Thomas¹^ORCID,Woetmann Anders¹^ORCID,Ødum Niels¹

Affiliation:

1. Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark;

2. Department of Dermatology, Aarhus University, Hospital, Skejby, Aarhus, Denmark;

3. Department of Dermatology, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark;

4. Division of Dermatology, McGill University, Montreal, QC, Canada;

5. Clinical Research Center, Lund University, Malmö, Sweden; and

6. Department of Molecular Biology, Umeå University, Umeå, Sweden.

Abstract

Key Points Individual patients with Sézary syndrome contain several distinct malignant subpopulations and show marked single-cell heterogeneity. Malignant subpopulations exhibit differences in their sensitivity to treatment warranting precision therapy.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/16/2115/881773/advances022608.pdf

Reference39 articles.

1. Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover;Krejsgaard;Semin Immunopathol,2017

2. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal;Agar;J Clin Oncol,2010

3. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL);Duvic;Blood,2007

4. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma;Piekarz;J Clin Oncol,2009

5. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management;Wilcox;Am J Hematol,2016

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous T-cell Lymphoma;Hematology/Oncology Clinics of North America;2024-10

2. Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature;Frontiers in Oncology;2024-08-07

3. Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre;Immunology Letters;2024-08

4. Delving into the Metabolism of Sézary Cells: A Brief Review;Genes;2024-05-17

5. Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon;Blood Advances;2024-05-17